Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: CNS tumours

278O - Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295

Date

09 Sep 2022

Session

Proffered Paper session: CNS tumours

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Jian Campian

Citation

Annals of Oncology (2022) 33 (suppl_7): S122-S135. 10.1016/annonc/annonc1047

Authors

J.L. Campian1, O. Butt2, J. Huang3, J. Luo4, Y. Tao4, R. Strowd5, D. Hissim5, S.H. Kizilbash1, C. Abraham3, G. Ansstas2, T. Johanns2, A. Kim6, M. Ciorba2, M. Chheda2

Author affiliations

  • 1 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 2 Medicine, Washington University School of Medicine in St. Louis - Siteman Cancer Center, 63110 - St. Louis/US
  • 3 Radiation Oncology, Washington University School of Medicine in St. Louis, 63110 - St. Louis/US
  • 4 Surgery, Washington University School of Medicine in St. Louis, 63110 - St. Louis/US
  • 5 Neurology, Wake Forest University Comprehensive Cancer Center, 27103 - Winston-Salem/US
  • 6 Neurosurgery, Washington University School of Medicine in St. Louis - Siteman Cancer Center, 63110 - St. Louis/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 278O

Background

Immunotherapies targeting the PD-1 pathway in recurrent glioblastoma (rGBM) have failed. We hypothesize that combining therapies targeting multiple immunosuppressive pathways with cytotoxic and antiangiogenic therapies will improve survival. Here, we evaluate the safety and efficacy of an anti-PD-1 monoclonal antibody (retifanlimab), hypofractionated radiotherapy (HFRT), and bevacizumab, with or without an oral IDO1 inhibitor (epacadostat), in patients with rGBM in a nonrandomized, noncomparative sequential two-arm phase II study.

Methods

This is an open-label phase II study of 2 sequential cohorts. Cohort A first examines retifanlimab (500mg IV Q4W)+ bevacizumab (10mg/kg IV Q2W) + HFRT (3.5Gy/day x10) in patients with IDH1/2-WT rGBM. After a toxicity monitoring period, Cohort B, which adds epacadostat (600mg PO BID), starts enrolling. Key inclusions include dexamethasone ≤ 4 mg/day and candidacy for reirradiation. The primary endpoint is OS probability at 9 months (OS-9). An increase of OS-9 from 38% (bevacizumab alone) to 60% is considered clinically relevant.

Results

We have completed accrual for cohort A and the interim analysis results are presented here: 25 rGBM enrolled, with 23 evaluable. Median age is 64.3 years (42.1-81.8), 30.4% female, 30.4% MGMT promotor methylated, median KPS 90 (range 70-100), baseline dexamethasone 0 mg (range 0-4), median baseline ALC 1,000 cells/μl (range 300-3,700). Patients received a median of 6 cycles to date (range 2-20). Median follow-up is 11.97 months per the reverse Kaplan-Meier method. Interim analysis shows a median PFS of 9.9 months (95%CI: 5.5 to not reached (NR)) and median OS of 12.2 months (95%CI 7.3-NR). Notably, Cohort A met the primary endpoint with an OS-9 of 71.4% (95%CI: 46.7% -86.1%). No dose limiting toxicities have been observed. Two treatment-related grade 3 toxicities have occurred (myositis, hypertension).

Conclusions

Interim analysis suggests retifanlimab combined with HFRT and bevacizumab in patients with rGBM is well-tolerated and had encouraging OS and PFS at the time of data cutoff. Cohort B, which adds epacadostat, is currently enrolling.

Clinical trial identification

NCT03532295.

Editorial acknowledgement

NA

Legal entity responsible for the study

The authors.

Funding

Incyte.

Disclosure

J.L. Campian: Non-Financial Interests, Institutional, Principal Investigator: Merck. A. Kim: Non-Financial Interests, Institutional, Funding: Monteris. M. Ciorba: Non-Financial Interests, Institutional, Funding: Incyte. M. Chheda: Non-Financial Interests, Institutional, Research Grant, PI for Orbus, Incyte and Merck trials: NeoImmuneTech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.